JP2022542247A - 不死化幹細胞株の製造方法およびその用途 - Google Patents
不死化幹細胞株の製造方法およびその用途 Download PDFInfo
- Publication number
- JP2022542247A JP2022542247A JP2022504118A JP2022504118A JP2022542247A JP 2022542247 A JP2022542247 A JP 2022542247A JP 2022504118 A JP2022504118 A JP 2022504118A JP 2022504118 A JP2022504118 A JP 2022504118A JP 2022542247 A JP2022542247 A JP 2022542247A
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- stem cell
- cells
- immortalized
- bdnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 293
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 139
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 230000005855 radiation Effects 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 19
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 93
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 88
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 88
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 34
- 231100000987 absorbed dose Toxicity 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 230000001678 irradiating effect Effects 0.000 claims description 16
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 15
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 210000001185 bone marrow Anatomy 0.000 claims description 11
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 208000025966 Neurological disease Diseases 0.000 claims description 6
- 208000036353 Rett disease Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000000532 Chronic Brain Injury Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 208000014644 Brain disease Diseases 0.000 claims description 3
- 102000009410 Chemokine receptor Human genes 0.000 claims description 3
- 108050000299 Chemokine receptor Proteins 0.000 claims description 3
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims description 3
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 208000033300 perinatal asphyxia Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 94
- 230000004663 cell proliferation Effects 0.000 abstract description 15
- 230000035755 proliferation Effects 0.000 abstract description 14
- 108700019146 Transgenes Proteins 0.000 abstract description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 45
- 229960003722 doxycycline Drugs 0.000 description 45
- 239000013598 vector Substances 0.000 description 39
- 108010080611 Cytosine Deaminase Proteins 0.000 description 35
- 241000713666 Lentivirus Species 0.000 description 35
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 33
- 102000000311 Cytosine Deaminase Human genes 0.000 description 28
- 239000002609 medium Substances 0.000 description 23
- 230000005757 colony formation Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 12
- 238000012790 confirmation Methods 0.000 description 11
- 101150035467 BDNF gene Proteins 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 239000004098 Tetracycline Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 229960002180 tetracycline Drugs 0.000 description 8
- 229930101283 tetracycline Natural products 0.000 description 8
- 235000019364 tetracycline Nutrition 0.000 description 8
- 150000003522 tetracyclines Chemical class 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 6
- 101710101011 GRB2-related adapter protein 2 Proteins 0.000 description 6
- 102100035414 Neurofascin Human genes 0.000 description 6
- 101710189786 Neurofascin Proteins 0.000 description 6
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 6
- 108700012411 TNFSF10 Proteins 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101150054149 ANGPTL4 gene Proteins 0.000 description 5
- 102100034594 Angiopoietin-1 Human genes 0.000 description 5
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 description 5
- 101000663658 Aptenodytes patagonicus Spheniscin-1 Proteins 0.000 description 5
- 101000663662 Aptenodytes patagonicus Spheniscin-2 Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 5
- -1 IF-γ Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 5
- 101710154942 Interleukin-2 receptor subunit beta Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 102100022546 Bone morphogenetic protein 8A Human genes 0.000 description 4
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 4
- 102100024001 Hepatic leukemia factor Human genes 0.000 description 4
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 4
- 101000903886 Homo sapiens Protein BEX2 Proteins 0.000 description 4
- 101000795292 Homo sapiens Tripartite motif-containing protein 6 Proteins 0.000 description 4
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 4
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102100031243 Polypyrimidine tract-binding protein 3 Human genes 0.000 description 4
- 101710132760 Polypyrimidine tract-binding protein 3 Proteins 0.000 description 4
- 102100022953 Protein BEX2 Human genes 0.000 description 4
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 4
- 108010017842 Telomerase Proteins 0.000 description 4
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 4
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000899364 Homo sapiens Bone morphogenetic protein 8A Proteins 0.000 description 3
- 101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 description 3
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 description 3
- 101000807008 Homo sapiens Uracil phosphoribosyltransferase homolog Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 101000938863 Toxoplasma gondii Uracil phosphoribosyltransferase Proteins 0.000 description 3
- 102100029673 Tripartite motif-containing protein 6 Human genes 0.000 description 3
- 102100037717 Uracil phosphoribosyltransferase homolog Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 102000051542 human BDNF Human genes 0.000 description 3
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 101150028326 CD gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000016788 immune system process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108091024545 miR-1244-1 stem-loop Proteins 0.000 description 2
- 108091047769 miR-1244-4 stem-loop Proteins 0.000 description 2
- 108091086075 miR-4444-1 stem-loop Proteins 0.000 description 2
- 108091089540 miR-4444-2 stem-loop Proteins 0.000 description 2
- 108091047835 miR319i stem-loop Proteins 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710117973 Bone morphogenetic protein 8A Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101710134031 CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150078582 FCY1 gene Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101150032426 HLF gene Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108050003766 Hepatic leukemia factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 101000638044 Homo sapiens Neurogenic differentiation factor 1 Proteins 0.000 description 1
- 101100426080 Homo sapiens TRIM6 gene Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 101150050263 ICAM1 gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 108010032220 cyclomaltodextrinase Proteins 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000028718 growth factor binding proteins Human genes 0.000 description 1
- 108091009353 growth factor binding proteins Proteins 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000011199 transformed cell apoptotic process Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
- C12N2529/10—Stimulation by light
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
不死化遺伝子を導入した幹細胞株を製作する段階と、
前記幹細胞株に外来タンパク質をコード化する遺伝子を導入する段階と、
前記幹細胞株を凍結保存する段階と、
前記凍結した状態の幹細胞株に放射線を照射する段階と、を含む不死化幹細胞株の製作方法を提供する。
1)宿主細胞にhTERTおよび/またはc-Myc遺伝子のような不死化遺伝子を導入する段階と、
2)前記不死化遺伝子が導入された宿主細胞に外来遺伝子を導入する段階。
照射線量0~100Gyであるとき、照射線量の90~110%;
照射線量100~200Gyであるとき、照射線量の85~115%;および
照射線量200Gy以上であるとき、照射線量の60~110%。
BDNF過発現;
ANGPTL4、ANGPT1、CEND1、NFASC、GRAP2またはTRIM6遺伝子の発現量増加;および
IL2RB、IL6、IL1BまたはPTGS2の発現量減少。
実施例1.1.不死化遺伝子を含むレンチウイルスベクターの製造
MSCを不死化させるために、不死化遺伝子c-Mycおよび/またはhTERTを含むレンチウイルスベクターを製造した。この際、Tet-offシステムを使用するために、tTAタンパク質を発現する遺伝子コンストラクトを共に挿入した。
前記実施例1.1.で製作されたレンチウイルスベクターを用いて、次のような方法で不死化遺伝子を含むレンチウイルスを生産した。
前記実施例1.2.で生産された不死化遺伝子を含むレンチウイルスを用いて不死化MSCを製造した。
実施例2.1.BDNF遺伝子を含むレンチウイルスの製作
前記実施例1.1.で製作したpBDレンチウイルスベクターに、BDNF遺伝子(配列番号2)を挿入した。
TRAILおよびCD遺伝子を含むレンチウイルスは、韓国登録特許第10-1985271号公報に記載された内容によって製作した。前記実施例1.1で製作されたpBDレンチウイルスベクターに、TRAIL遺伝子(配列番号4)およびCD遺伝子(配列番号6)を挿入した。この際、挿入されたTRAILおよびCD遺伝子がIRES(internal ribosome entry site)に連結され、TREプロモーターによって発現が調節されるようにした。IRESは、リボソーム結合部位であり、5’-キャップ構造がなくても翻訳(translation)が開始できるようにして、一つのmRNAで2つのタンパク質が発現できるようにする。一方、TREプロモーターは、ドキシサイクリンの添加有無によって前記プロモーターと連結された遺伝子の発現を調節できる。
実施例3.1.BDNF遺伝子を含むレンチウイルスで形質感染したMSCの製作
3.1.1.BM102細胞株の製作
前記実施例1.3.で製造した不死化MSCに、前記実施例2.1.で生産したBDNF遺伝子を含むレンチウイルスを100MOI感染させて、BDNF遺伝子を発現する細胞を製造した。ここで、前記レンチウイルスは、不死化遺伝子のうちc-Mycが導入されたpBD-1ベクターによって生産されたものを使用した。形質導入された細胞は、2μg/mlのドキシサイクリン(doxycycline、631311、Clontech、米国)が添加された培地で培養することによって、培養中にBDNFタンパク質の発現を抑制させた。
また、前記3.1.1と同一に、pBD-1とpBD-2を導入したレンチウイルスによって感染させた不死化MSCを製作した。前記細胞株の製造方法は、韓国登録特許第10-2074336号に記載された方法によって製作した。ウイルス感染後、細胞を安定化させた後、培養液に500μg/mlのG418を添加して、c-MycおよびhTERT遺伝子が両方とも導入されたpBD-5レンチウイルスに感染した細胞を選別した。選別された細胞は、1μg/mlのドキシサイクリン(doxycycline、631311、Clontech、米国)が添加された培地で培養することによって、培養中にBDNFタンパク質の発現を抑制した。
韓国登録特許第10-1985271号に記載された方法によって、前記実施例1-3で製造した不死化MSCに、前記実施例2-2で生産したTRAILおよびCD遺伝子を含むレンチウイルスを感染させて、TRAILおよびCD遺伝子を発現する細胞を製造した。感染は、実施例1-3の記載と同じ方法で行われた。感染後、安定化した細胞の培養液に1μg/mlのドキシサイクリン(doxycycline、631311、Clontech、米国)を添加して、TRAILおよびCDの発現を抑制させた状態で培養した。細胞が安定化した後、ドキシサイクリンを除去した培養培地で72時間培養してTRAILおよびCDの発現を誘導させ、前記細胞でFACSを行って、細胞表面にTRAILを発現する細胞を選別した。
前記実施例3で製作されたそれぞれの不死化MSC細胞株を臨床試料として使用するために、細胞が増殖することなく、治療タンパク質の発現量を維持させるための放射線照射段階をさらに実施し、これを通じて好適な放射線照射(吸収)線量を確認した。
遺伝子を挿入する前の骨髄由来MSCとBDNF遺伝子が挿入されたBM102細胞株の表面抗原タンパク質発現をヒトMSC分析キット(StemflowTM、Cat No562245、BD)を用いて分析した。実験は、各キットに含まれているマニュアルに沿って行われ、実験結果を図4に示した。
前記実施例3.1.で確立したBM102細胞株の増殖率を確認した。T175フラスコに0.2×106~0.8×106個のBM102細胞株を接種した後、ドキシサイクリンを添加するかまたは添加せず、3日または4日培養を進め、PDL(population Doubling Level)と細胞生存率を測定した。PDLは、「PDL=X+3.222(logY-logI)」公式によって計算し、Xは初期PDL、Iはフラスコに接種された初期細胞数、Yは最終細胞数を示した。確立された細胞株の増殖率を図5および図6に示した。
前記実施例3.1.で確立したBM102細胞株の継代培養による形態学的変形を確認するために、実験例2.でBM102細胞株の増殖率を確認しつつ、顕微鏡で細胞の写真を撮影し、BM102細胞の形態を図7に示した。
前記実施例3.1.で確立したBM102細胞においてBDNFタンパク質の発現をELISA分析方法で確認した。具体的に、BDNFタンパク質の発現レベルは、ヒトBDNF DuoSet ELISAキットで確認した。実験は、各キットに含まれているマニュアルに沿って行われた。ドキシサイクリンを除去した培地とドキシサイクリンを除去しない培地で約1×105個の細胞から48時間発現が誘導されたBDNFタンパク質の発現レベルを図8に示した。
前記実施例3.1.で製造したBM102細胞株に遺伝子が導入されたかを確認するためにPCRを行った。具体的に、前記BM102細胞株を9mlのPBSが含まれた15mlチューブに移した後、1,500rpmで5分間セルダウン(Cell Down)させた。PBSを完全に除去した後、1.5mlチューブに200μlのPBSでペレットを懸濁させた後に移した。その後、NucleoSpin(登録商標)Tissue(MN、740952.250)を用いてgDNAを準備し、下記表2のように混合物を作成した後、下記表3の段階でPCRを行った。この際、陽性対照群として100ngのBM102プラスミドDNAを、陰性対照群として1μlの精製水を入れた。前記BM102プラスミドDNAは、韓国公開特許第2017-0093748号に記載された方法によって分離精製できる。
前記実施例3.1.で製造したBM102細胞株においてドキシサイクリン処理の有無によるBDNF発現による遺伝子の発現変化を確認するために、転写産物の塩基配列分析(transcriptome sequencing)を行った。
BM102細胞株に対して、ガンマ線およびエックス線を用いて放射線照射試験を実施例4のような方法で進め、照射される放射線の種類は、ガンマ線およびエックス線を使用した。
BM102細胞株に対して、ガンマ線およびエックス線を前記範囲でそれぞれ照射後、コロニー形成の有無を確認するために、6-wellプレートでwellに5×105個の細胞になるように、バイアル当たり12個のwellに分注して、合計2個の6-wellプレートに分注した。プレートを振とうして細胞が均一に広がるようにし、37℃、5%CO2培養器で3日あるいは4日ごとに培地を交換しつつ、顕微鏡を用いてコロニーが形成されるかを目視で観察した。
前記コロニー形成の有無の試験のために接種された細胞を用いて細胞数測定試験を実施した。前記実験例7でガンマ線が照射されたBM102細胞株に対して、細胞解凍日を基準としてDay 7、14、28、35、49、63日にそれぞれ付着した細胞をトリプシンを用いて脱離させた後、トリパンブルー(Trypan blue)染色を行い、ヘモサイトメーター(Hemocytometer)を用いて総細胞数と生存細胞数の個数を計数した。
前記実験例7で放射線を照射したBM102細胞の一部は、力価試験のために12-wellプレートでwellに1×105または5×105個の細胞になるように、バイアル当たり合計1個のwellに分注した。プレートを振とうして細胞が均一に広がるようにし、37℃、5%CO2培養器で48時間または60時間培養した。
実験例7と同じ方式で、BM01A細胞株に対する放射線照射試験を実施した。照射される放射線の種類は、ガンマ線を使用し、照射線量90、100、110、120Gyのガンマ線を一次に照射した後、吸収線量と、コロニー形成の有無、細胞数および力価を確認し、照射線量140、160、180Gyのガンマ線を2次に照射した後、同じ方法で吸収線量、コロニー形成の有無、細胞数および力価をそれぞれ確認した。その結果を下記表9に記載した。
BM01A細胞株を6-wellプレートで3×105 cell/wellの数で分注し、前記実験例7.1.と同じ方法で培養した後、培地でコロニー形成の有無を確認した。
前記実験例7.2.と同じ方法で、ガンマ線が照射されたBM01A細胞株の細胞数測定実験を実施した。
前記実験例8で放射線照射されたBM01A細胞株の力価試験のために、実験例7.3.と同じ方法で細胞を培養および冷凍保管した。BM01AのBDNF発現量は、BDNF分析キット(DY248、R&D systems、米国)を用いて分析した。
TRAILおよびCDを発現する不死化幹細胞BM03細胞株に対して、実験例7と同じ方式で放射線照射試験を実施した。BM03菌株の放射線照射試験はガンマ線を活用し、低準位および高準位ガンマ線をそれぞれ照射して、その結果を確認した。
前記実験例9のBM03細胞に対するコロニー形成の有無を確認するために、前記実験例7.1.と同じ方式で細胞株のコロニー形成の有無を確認した。前記実験例9で、低準位ガンマ線が照射されたBM03および高準位ガンマ線が照射されたBM03に対してコロニー形成の有無を確認した結果、前記表11および表12から明らかなように、低準位ガンマ線の照射時に、特に50Gy以下の照射線量でコロニーが形成され、高準位ガンマ線の照射時には、60Gy以下の照射線量でコロニーが形成されて、臨床試料として使用するのに適していないことを確認した。しかしながら、低準位ガンマ線の場合、70Gy以上、高準位ガンマ線の場合、100Gy以上では、コロニーが形成されないことを確認した。
実験例9.1.で培養される細胞に対して、低準位ガンマ線が照射されたBM03細胞株の場合、細胞解凍日からそれぞれ2、7、14、28、35、42、49日に付着した細胞の数を計数して、培養された細胞数の増加の有無を確認した。
放射線照射後、細胞の力価の変化を測定するために、挿入された治療遺伝子TRAILとCD::UPRTを確認できるプライマーを選定した後、qRT-PCR反応を通じて挿入された遺伝子の発現を定量的に測定した。
CytoSelectTM 96-well Cell Transformation Assayを用いてソフト寒天ゲル(Soft Agar Gels)で骨髄由来MSC、BM102細胞株、陽性対照群(HeLa)および陰性対照群(NIH3T3)において足場非依存性増殖(Anchorage-independent Growth)によるコロニー形成の有無を確認し、MTS溶液で染色して、吸光度を測定することによって、細胞形質転換による腫瘍形成の有無を定量化した。
BM102細胞株の神経細胞の保護および治療効果を確認するために、BDNFによって良好に成長することが知られた神経膠細胞C6をBM102細胞株と共培養した後、C6細胞の増殖率の増加を細胞数依存的に確認した。
受託番号:KCTC13876BP
受託日:20190702
Claims (13)
- 不死化遺伝子を導入した幹細胞株を製作する段階と、
前記幹細胞株に外来タンパク質をコード化する遺伝子を導入する段階と、
前記幹細胞株を凍結保存する段階と、
前記凍結した状態の幹細胞株に放射線を照射する段階と、を含む、不死化幹細胞株の製作方法。 - 前記不死化遺伝子は、c-Mycおよび/またはhTERTである、請求項1に記載の不死化幹細胞株の製作方法。
- 前記外来タンパク質は、成長因子、サイトカインまたはがん治療タンパク質、抗体およびケモカイン受容体の中から選ばれる、請求項1に記載の不死化幹細胞株の製作方法。
- 前記不死化幹細胞株は、ヒト胚性幹細胞(human embryonic stem cell,hES)、骨髄幹細胞(bone marrow stem cell,BMSC)、間葉系幹細胞(mesenchymal stem cell,MSC)、ヒト神経幹細胞(human neural stem cell,hNSC)、角膜上皮幹細胞(limbal stem cell)または口腔粘膜上皮細胞(oral mucosal epithelial cell)である、請求項1に記載の不死化幹細胞株の製作方法。
- 前記放射線は、幹細胞株に対する吸収線量が少なくとも80Gyになるように照射される、請求項1に記載の不死化幹細胞株の製作方法。
- 前記幹細胞株に対する吸収線量は、放射線照射線量に対して、下記の範囲を満たす、請求項5に記載の不死化幹細胞株の製作方法。
照射線量0~100Gyであるとき、照射線量の80~140%;
照射線量100~200Gyであるとき、照射線量の80~140%;および
照射線量200Gy以上であるとき、照射線量の60~140%。 - 前記放射線は、ガンマ線、ベータ線、中性子線、エックス線および電子線を含む群から選ばれる、請求項1に記載の不死化幹細胞株の製作方法。
- 請求項1に記載の方法によって製作された不死化幹細胞株を含む薬剤学的組成物。
- 前記薬剤学的組成物は、脳由来神経栄養因子(BDNF)を発現する不死化幹細胞株を含む、請求項8に記載の薬剤学的組成物。
- 前記薬剤学的組成物は、神経疾患の予防または治療効果を有する、請求項9に記載の薬剤学的組成物。
- 前記神経疾患は、アルツハイマー病(Alzheimer’s disease,AD)、パーキンソン病(Parkinson’s disease,PD)、ルーゲリック病(Amyotrophic Lateral Sclerosis,ALS)、脳梗塞、慢性脳損傷(chronic brain injury)、脊髄損傷、ハンチントン病(Huntington’s disease,HD)、レット病(Rett’s disease,RD)、虚血性脳疾患、脳卒中および外傷性脳損傷(Traumatic brain injury)、新生児虚血性脳症(Neonatal Hypoxic ischemic encephalopathy)、多発性硬化症からなる群から選ばれるものである、請求項10に記載の神経疾患の予防または治療用薬剤学的組成物。
- 請求項1に記載の方法によって製作された不死化幹細胞株の細胞治療剤としての用途。
- 請求項1に記載の方法によって製作された不死化幹細胞株を治療的に有効な量で個体に投与して疾患を治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0089897 | 2019-07-24 | ||
KR20190089897 | 2019-07-24 | ||
PCT/KR2020/009769 WO2021015584A1 (ko) | 2019-07-24 | 2020-07-24 | 불사화된 줄기세포주의 제조 방법 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022542247A true JP2022542247A (ja) | 2022-09-30 |
Family
ID=74193282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022504118A Pending JP2022542247A (ja) | 2019-07-24 | 2020-07-24 | 不死化幹細胞株の製造方法およびその用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220282220A1 (ja) |
EP (1) | EP4006145A4 (ja) |
JP (1) | JP2022542247A (ja) |
KR (1) | KR20210012966A (ja) |
CN (1) | CN114729324A (ja) |
WO (1) | WO2021015584A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019147036A1 (ko) * | 2018-01-24 | 2019-08-01 | 주식회사 에스엘바이젠 | 뇌유래-신경영양인자를 발현하는 중간엽줄기세포 및 이의 용도 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223183A1 (en) * | 2005-03-11 | 2006-10-05 | Bates Steven E | Gamma irradiation of frozen feeder cells |
EP3000875A1 (en) * | 2014-09-25 | 2016-03-30 | Philipps-Universität Marburg | Method for manufacturing of a composition comprising ex vivo expanded human mesenchymal stromal cells |
JP2016532717A (ja) * | 2013-09-27 | 2016-10-20 | ヴァクシノゲン インターナショナル パートナーズ, エルピーVaccinogen International Partners, Lp | 自己腫瘍ワクチン及び方法 |
JP2017123867A (ja) * | 2008-03-27 | 2017-07-20 | アステリアス バイオセラピューティクス インコーポレイテッド | 霊長類多能性幹細胞の造血系統細胞への分化 |
KR20170093748A (ko) * | 2016-02-05 | 2017-08-16 | 주식회사 에스엘바이젠 | Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도 |
WO2019004795A2 (ko) * | 2017-06-30 | 2019-01-03 | 코오롱생명과학 주식회사 | 세포치료제의 유효성 평가 방법 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338678A (en) | 1989-06-09 | 1994-08-16 | Oncogen, A Limited Partnership | Expression of DNA sequences encoding a thermally stable cytosine deaminase from saccharomyces |
US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
GB9827103D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
EP1103601B1 (en) * | 1999-11-26 | 2008-11-19 | Menicon Co., Ltd. | Method for culturing cells |
US20050084959A1 (en) * | 2001-10-31 | 2005-04-21 | Hirofumi Hamada | Immortalized mesenchymal cells and utilization thereof |
US20040191229A1 (en) * | 2002-10-09 | 2004-09-30 | Link Charles J. | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
IN2014DN06624A (ja) * | 2005-10-18 | 2015-07-10 | Univ Colorado | |
AU2014202016B2 (en) * | 2005-10-18 | 2016-05-19 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
CN101182488A (zh) * | 2007-11-16 | 2008-05-21 | 中国医学科学院基础医学研究所 | 间充质干细胞的一种新用途 |
BRPI1012971A2 (pt) * | 2009-06-11 | 2018-01-16 | Angiochem Inc | proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central |
CN102174578A (zh) * | 2011-01-25 | 2011-09-07 | 天津医科大学眼科中心 | 一种慢病毒载体及其介导的分泌脑源性神经营养因子的骨髓间充质干细胞系的制备方法 |
CN103045540A (zh) * | 2011-10-14 | 2013-04-17 | 北京清美联创干细胞科技有限公司 | 促使骨髓间充质干细胞在大鼠脑内分化成神经元的新方法 |
CN104471059B (zh) * | 2012-07-12 | 2018-04-17 | 珠海横琴爱姆斯坦生物科技有限公司 | 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 |
KR20140057505A (ko) * | 2014-03-24 | 2014-05-13 | 주식회사 제넨메드 | h-TERT 유전자를 포함하는 종양세포 불멸화용 조성물 |
KR101741182B1 (ko) * | 2014-07-15 | 2017-05-30 | 주식회사 녹십자랩셀 | 뇌신경계 질환 치료용 물질을 발현하는 줄기세포를 포함하는 비강내 투여용 조성물 |
KR101585032B1 (ko) | 2015-04-30 | 2016-01-14 | (주)안트로젠 | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 |
CN109477119A (zh) * | 2016-02-04 | 2019-03-15 | 斯比根公司 | 表达肝细胞生长因子的间充质干细胞及其用途 |
KR20190015153A (ko) * | 2017-08-04 | 2019-02-13 | 주식회사 에스엘바이젠 | 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물 |
WO2019147036A1 (ko) | 2018-01-24 | 2019-08-01 | 주식회사 에스엘바이젠 | 뇌유래-신경영양인자를 발현하는 중간엽줄기세포 및 이의 용도 |
-
2020
- 2020-07-24 EP EP20843159.3A patent/EP4006145A4/en active Pending
- 2020-07-24 US US17/629,591 patent/US20220282220A1/en active Pending
- 2020-07-24 KR KR1020200092259A patent/KR20210012966A/ko unknown
- 2020-07-24 CN CN202080063203.9A patent/CN114729324A/zh active Pending
- 2020-07-24 WO PCT/KR2020/009769 patent/WO2021015584A1/ko unknown
- 2020-07-24 JP JP2022504118A patent/JP2022542247A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223183A1 (en) * | 2005-03-11 | 2006-10-05 | Bates Steven E | Gamma irradiation of frozen feeder cells |
JP2017123867A (ja) * | 2008-03-27 | 2017-07-20 | アステリアス バイオセラピューティクス インコーポレイテッド | 霊長類多能性幹細胞の造血系統細胞への分化 |
JP2016532717A (ja) * | 2013-09-27 | 2016-10-20 | ヴァクシノゲン インターナショナル パートナーズ, エルピーVaccinogen International Partners, Lp | 自己腫瘍ワクチン及び方法 |
EP3000875A1 (en) * | 2014-09-25 | 2016-03-30 | Philipps-Universität Marburg | Method for manufacturing of a composition comprising ex vivo expanded human mesenchymal stromal cells |
KR20170093748A (ko) * | 2016-02-05 | 2017-08-16 | 주식회사 에스엘바이젠 | Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도 |
WO2019004795A2 (ko) * | 2017-06-30 | 2019-01-03 | 코오롱생명과학 주식회사 | 세포치료제의 유효성 평가 방법 |
Non-Patent Citations (5)
Title |
---|
FRONTIERS IN IMMUNOLOGY, 2019年7月16日, vol. 10, JPN6023009201, pages 1627 - 1, ISSN: 0005008643 * |
GENOME RESEARCH, 2013年, vol. 23, JPN6023009200, pages 248 - 259, ISSN: 0005008644 * |
INT. J. MOL. SCI. 2016年, vol. 17, JPN6023009198, pages 1 - 18, ISSN: 0005008646 * |
INT. J. RADIAT. ONCOL. BIOL. PHYS. 2009年, vol. 75, no. 3, JPN6023009197, pages 843 - 853, ISSN: 0005008647 * |
TISSUE ENGINEERING: PART C, 2015年, vol. 21, no. 2, JPN6023009199, pages 112 - 122, ISSN: 0005008645 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210012966A (ko) | 2021-02-03 |
WO2021015584A1 (ko) | 2021-01-28 |
US20220282220A1 (en) | 2022-09-08 |
EP4006145A1 (en) | 2022-06-01 |
CN114729324A (zh) | 2022-07-08 |
EP4006145A4 (en) | 2023-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220401491A1 (en) | Mesenchymal stem cell expressing trail and cd, and use thereof | |
US20220401518A1 (en) | Mesenchymal stem cell expressing hepatocyte growth factor, and use thereof | |
CN106102754B (zh) | 癌治疗用医药组合物以及将该组合物作为有效成分的癌治疗用医药制剂 | |
JP2003527817A (ja) | 遺伝子修飾したcd34−陰性付着成長性幹細胞および遺伝子療法におけるそれらの使用 | |
Santos et al. | Leukemia inhibitory factor (LIF) overexpression increases the angiogenic potential of bone marrow mesenchymal stem/stromal cells | |
Xue et al. | Bcl-xL genetic modification enhanced the therapeutic efficacy of mesenchymal stem cell transplantation in the treatment of heart infarction | |
JP2016520296A (ja) | Hmga2を用いて非神経細胞からリプログラミングされた誘導神経幹細胞を調製する方法 | |
JP7016556B2 (ja) | 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途 | |
CN114423860A (zh) | 包含病毒载体的细胞组合物及治疗方法 | |
US20220282220A1 (en) | Method for preparation of immortalized stem cell line and use thereof | |
JP2008228632A (ja) | 卵巣顆粒膜細胞または卵巣夾膜細胞への分化誘導能を持つ成体体性幹細胞 | |
KR102546749B1 (ko) | 골격근 세포 및 이의 유도 방법 | |
KR101269125B1 (ko) | 노치 신호 활성 유전자를 이용한 줄기세포의 증식 방법 | |
CN109402061B (zh) | 一种可以延缓细胞衰老及抵抗恶性转化的人间充质干细胞及其制备方法和应用 | |
WO2019027298A9 (ko) | Trail 및 cd를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 암의 예방또는 치료용 약학 조성물 | |
WO2023176806A1 (ja) | 線維芽細胞または線維芽細胞様細胞を従来型2型樹状細胞にリプログラミングするための方法 | |
KR102285613B1 (ko) | 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도 | |
RU2521225C2 (ru) | Способ стимулирования регенерации спинного мозга с помощью генетически модифицированных клеток крови пуповины человека | |
WO2023167243A1 (ja) | 不死化間葉系幹細胞の上清を含む脱髄疾患治療用医薬組成物、及びその組成物を有効成分とする医薬製剤 | |
KR102100490B1 (ko) | 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도 | |
WO2022153996A1 (ja) | 間葉系幹細胞、抗炎症剤及び神経疾患治療剤 | |
KR20220000688A (ko) | 뇌 유래 신경영양인자를 발현하는 불사화된 줄기세포주를 포함하는 저산소성 허혈성 뇌병증의 치료용 약학적 조성물 | |
KR20240009417A (ko) | 욕창의 예방제 및/또는 치료제 | |
JP2022104986A (ja) | 細胞融合技術を用いた遺伝子及び細胞治療剤、並びにその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231220 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240423 |